USRE35748E - Treatments employing drug containing matrices for introduction into cellular lesion areas - Google Patents
Treatments employing drug containing matrices for introduction into cellular lesion areas Download PDFInfo
- Publication number
- USRE35748E USRE35748E US08/574,498 US57449895A USRE35748E US RE35748 E USRE35748 E US RE35748E US 57449895 A US57449895 A US 57449895A US RE35748 E USRE35748 E US RE35748E
- Authority
- US
- United States
- Prior art keywords
- drug
- collagen
- baddend
- badd
- iadd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Definitions
- cytotoxic drugs exert their activity in a variety of ways, usually interfering with a cellular function essential for the replication and/or viability of the cell. In many, if not most, instances, the drug is not specific for the unnatural cell, but rather tends to exert its effectiveness due to the more rapid proliferation of the abnormal cell, as compared to normal cells. While many organs of the body of a mammalian host regenerate cells rather slowly, there are also other organs, particularly bone marrow, which involves rapid proliferation of stem cells. Therefore, the cytotoxic agents not only can detrimentally affect the slowly regenerating cells, but also have a particularly pernicious effect on the immune system.
- Abnormal solid cellular growth, particularly tumors, or adjacent tissue that may contain tumor cells are treated by injecting into the abnormal growth area or tissue suspected of containing tumor cells a sufficient mount of a cytotoxic drug dispersed in a stable flowable proteinaceous matrix.
- the resulting matrix substantially inhibits the migration of the drug from the site of injection, so as to maintain the primary effect of the drug in the region of injection. Migration can be further inhibited by the use of physiologically acceptable materials which enhance the binding of the drug to the matrix or which modify cellular properties or physiological responses to further regionalize the placement of drug at the injection site.
- Novel methods and compositions are provided for the chemotherapeutic treatment of solid abnormal tumors, cellular growth, or particularly, adjacent tissues which may contain abnormal tumor cells.
- the method employs a substantially uniform dispersion of a chemotherapeutic drug in a concentrated dispersion of a physiologically acceptable matrix, particularly a protein such as collagen, fibrinogen, or a derivative thereof, or other high molecular weight physiologically acceptable biodegradable composition, dispersed in a minor amount of a physiologically acceptable aqueous medium.
- the resulting amorphous mass is injected into the lesion, e.g., tumor, or lesion area, e.g., adjacent tissue, or in those situations where the minor has been removed, tissue adjacent to the previously removed tumor.
- the proteinaceous matrix is flowable for injection, but provides for stable placement, once injected into the tissue. That is, once injected the proteinaceous matrix adheres to the tissue and does not migrate significantly.
- the treatment may be employed with various solid tumors, including carcinomas and sarcomas. After injection, the drug is released into the immediate environment, so as to prevent substantial transportation of the drug to other sites, where its cytotoxic effect is undesirable. Thus, the circulating blood level of the drug remains low. In this way an enhanced therapeutic gain is achieved, that is, the cytotoxic effect on malignant cells is greater as compared to susceptible normal cells.
- Neoplasms in which local recurrence is typical and drug bioavailability is compromised e.g., brain
- tumors in which suspected neoplastic cells remain in the tumor bed following surgical resection, e.g., breast e.g., breast
- tumors which are poor candidates for surgical or radiation management e.g., head, neck, prostate, etc.
- adjunctive tumor therapy in combination with physical or non-chemical treatments, e.g., radiation and/or hyperthermia
- hyperproliferative diseases refractory to conventional therapy e.g., psoriasis
- concurrent with systemic chemotherapy (7) concurrent with systemic rescue, e.g., methotrexate, plus collagen matrix intra-tumorally, leucovorin i.v.
- compositions are amorphous, injectable and viscous, so as to substantially retain a localized position without significant flow from the site of administration.
- the compositions can flow under moderate pressure, but will not move significantly after being positioned at a particular site.
- the protein will be capable of binding the agents covalently or non-covalently, without preventing their therapeutic effect, while retaining the active agents at the site of introduction or retarding transfer of the active agents present from the site of introduction.
- the composition will be comprised of a significant amount of the matrix to provide the desired composition characteristics.
- the matrix may be comprised of individual or in combination peptides or proteins, e.g., structural proteins such as collagen and fibrinogen, or albumin or other protein which provides for stable placement, or combinations thereof. Of particular interest is collagen, fibrinogen or derivative thereof.
- Proteinaceous compositions having at least about 5 weight percent, preferably at least about 10 weight percent, and up to 50 weight percent or more, are of particular interest when used in combination with thrombin or its enzymatic equivalent. In this way fibrinogen is enzymatically modified to fibrin to enhance the non-migratory property of the composition while forming a matrix of fibrils to further stabilize the composition.
- the thrombin may be mixed with fibrinogen containing proteinaceous composition from a time immediately prior to use or shortly after injection.
- the amount of thrombin of about 1 to 1000 IU/mg employed will generally range from about 0.1 to 10 weight percent of the fibrinogen present, depending upon the time of use, the rate desired for solid matrix formation, the amount of other components, the effect of the drug on thrombin activity, and the like.
- the matrix material will be one or more chemotherapeutic drugs, and a physiologically acceptable aqueous medium in which the proteinaceous composition is dispersed and the drug may be dissolved, dispersed, or complexed with the collagen.
- Other materials are preferably present to enhance the beneficial properties of the subject composition.
- the proteinaceous, particularly collagenous or fibrinogen-containing, material which is used may be derived from any mammalian host source, such as bovine, porcine or human, or may be prepared, as available, by other techniques, e.g. recombinant DNA techniques.
- the collagen employed may be natural collagen or may be modified, such as tropocollagen, atropocollagen, or the like.
- the collagen may be non-immunogenic, immunogenic, or only slightly immunogenic.
- chemotherapeutic drugs may be employed individually or in combination.
- the drugs may be bound or unbound to the matrix, through such binding as complexation, salt formation, coordination complexes, or the like, but any binding should not result in significant diminution of the physiological activity of the drug.
- Various drugs may be employed which are used in chemotherapy and act as alkylating agents, enzyme inhibitors, proliferation inhibitors, lytic agents, DNA synthesis inhibitors, membrane permeability modifiers, DNA intercalators, antimetabolites, or the like.
- Illustrative drugs include chlorambucil, melphalan, busulfan, carmustine, lomustine, streptozotocin, thiotepa, decarbazine methotrexate, 5-fluorouracil, cytarabine, azaribine mercaptopurine, thioguanine, vinblastine, vincristine, antinomycin D, adriamycin, bleomycin, mithramycin, mitomycin C, L-asparaginase, cisplatin, procarbazine, prednisone, prednisilone, triamicinolone, testosterone, estrogen, insulins, and hydroxyurea. See Carter and Livingston, Drugs Available to Treat Cancer.
- the drugs may be used individually or in combination, depending upon the nature of the drug, the tumor, and whether cooperative action is pharmacologically indicated.
- the drug composition can be further modified, by modifying the drug, particularly by bonds which allow for enzymatic cleavage, e.g., hydrolysis, or by introducing materials into the composition which will aid in the maintenance of the retention of the drug at the site of introduction.
- Various techniques can be used for diminishing drug migration, for example, by coupling the drug with specific ligands, such as lipids, phospholipids, peptides, amino acids, sugars, or the like. These modifications will depend upon the individual drug, varying the solubility of the drug in the aqueous medium and providing for covalent or non-covalent interactions with the protein.
- various physiologically acceptable bulking agents or concentrating agents may be employed, which serve to provide for drug and protein interactions, with resulting reduction in the rate of drug release.
- Illustrative materials include inorganic substances, such as hydroxyapatite and organic substances such as carbohydrates, e.g, agarose and cellulose.
- drugs for use in combination with the chemotherapeutic agents are drugs which retard the diffusion away of the chemotherapeutic agent, so as to reduce physiological insult and enhance therapeutic gain.
- agents which restrict regional vasculature, either as to growth and/or passage opening e.g., vasoconstrictive or sympathomimetic agents.
- agents may include catechol amines, e.g., epinephrine and nor-epinephrine ergot alkaloids, prostaglandins, angiotensin or the like.
- agents for affecting tissue architecture include enzymes which can injure the stroma, such as the peptidases papain, chymopapain, trypsin, amylase, collagenase and chymotrypsin.
- agents affecting cellular permeability may be employed, such as non-ionic detergents, e.g., Tween 80, amphotericin B, dimethylsulfoxide and anaesthetics, such as procaine.
- the drug(s) can be employed encapsulated in liposomes or other controlled rate release compositions, which are included in the proteinaceous composition, so as to provide for separate and distinct rates of release of the drug.
- multiphasic compositions can be prepared, so as to provide for sustained release of the drug over long periods of time. Formation of liposomes with inclusion of various materials is described in Papahadjopoulos (1978) Annals of the N.Y. Academy of Science, 308; Gregoriadis and Allison (1980) Liposomes in Biological Systems, John Wiley and Sons, Leserman et al., Nature (1981) 293:226-228; Barhet et al, Supramol. Struct. Cell Bio. Chem.
- Illustrative adjuvants include Corynebacterium parvum, Bacillus Calmette-Guerin cell wall or cell wall skeleton preparations, Mycobacterium bovis strain, etc. See Miyata et al., Cancer Res. (1983) 43:4670-4675; Bier et al., Arch. Otorhinolaryngol, (1982) 236:245-255; and Mehanjhlin et al., Cancer Res. (1978) 38:1311-1316, whose relevant disclosure is incorporated herein by reference.
- various adjuvant materials may be incorporated into the matrix, such as radioactive pellet, e.g., radionuclides Technicium or Iridium; radiation sensitizers, e.g., misonidazole; repair inhibitors, e.g., methylated xanthines; bioreductive agents, which are activated only in hypoxic cells; immunomodifiers, such as interferons, lymphokines, such as interleukin-2; tumor growth inhibitors, such as tumor necrosis factor, tumor growth factor- ⁇ , etc., and/or angiographic contrast media.
- radioactive pellet e.g., radionuclides Technicium or Iridium
- radiation sensitizers e.g., misonidazole
- repair inhibitors e.g., methylated xanthines
- bioreductive agents which are activated only in hypoxic cells
- immunomodifiers such as interferons, lymphokines, such as interleukin-2
- the ratio of dry materials in the composition may vary widely.
- the amount of protein matrix material will usually be not less than 30% and not greater than about 95%, generally ranging from about from 40% to 90%, more usually ranging from about 50% to 90% by weight. Of this, preferably 10 to 100% will be collagen and/or fibrinogen.
- the chemotherapeutic drug(s) will normally be a liquid or solid, or provided in solid form and a generally range from at least about 0.1% by weight to up to about 50% by weight, more usually being from about 1% to 50% by weight, generally being from about 1% to 45% by weight of the proteinaceous material.
- ancillary additives or agents will vary in total amount from about 0.005 to 15, usually from about 0.01 to 10 weight percent of the dry weight of the total composition.
- the composition is uniformly dispersed in a physiologically acceptable aqueous medium, such as saline, phosphate buffered saline, distilled water, etc.
- a physiologically acceptable aqueous medium such as saline, phosphate buffered saline, distilled water, etc.
- the aqueous medium will be sufficient to provide for an amorphous dispersion capable of flowing under mild pressure.
- the liquid aqueous medium will be at least 90 weight percent of the entire composition, more usually at least 95% weight percent, and not more than about 99.8 weight percent, usually not more than about 99.5 weight percent, so as to provide a flowable mixture.
- the amount will vary depending upon the nature of the drug(s), the nature of the matrix material, the presence of other materials, and the like.
- the concentration of protein in the aqueous medium will range from about 5 to 75 mg/ml.
- a number of minor components may also be included for a variety of purposes. These agents will for the most part impart properties which protect the stability of the composition, control the pH, or the like. Illustrative agents include phosphate or acetate buffers, methyl or propyl paraben, polyethylene glycols, etc. These agents generally will be present in less than about 2 weight percent of the total composition, usually less than about 1 weight percent, and individually may vary from about 0.001 weight percent to about 1 weight percent.
- the drug will be encapsulated particularly in liposomes.
- Liposomes are prepared from a variety of lamellar-forming lipids including phospholipids, e.g., phosphatidylcholine, phosphatidylethanolamine, etc., gangliosides, sphingomyelins, steroids, e.g., cholesterol, etc.
- the weight of the lipids in relation to the weight of drug will range from 1 to 5 L of entrapped drug per mole of amphiphatic lipid.
- the composition can be prepared by combining the various components in a sterile environment.
- the matrix will be provided in a convenient form, usually admixed with at least a portion of the total aqueous medium to be employed.
- the composition will be sufficiently workable that upon admixture of the other agents a uniform dispersion can be obtained.
- the collagenous material will normally be provided as a uniform dispersion of collagen fibrils in an aqueous medium, where the collagenous material will be from about 5 mg/ml to not more than 100, usually not more than 75 mg/ml.
- the drug may then be added to the collagenous dispersion with agitation to ensure the uniform dispersion of the drug in the resulting mixture.
- Other materials, as appropriate, may be added concomitantly or sequentially. After ensuring the uniform dispersion of the various components in the mixture, the mixture may be sterilized and sealed in appropriate container.
- Sterilization will usually be achieved using aspetic conditions.
- the subject composition can be used in the treatment of a wide variety of neoplastic lesions.
- Illustrative tumors include carcinomas, sarcomas and melanomas, such as basal cell carcinoma, squamous cell carcinoma, melanoma, soft tissue sarcoma, solar keratoses, Kaposi's sarcoma, cutaneons malignant lymphoma, Bowen's disease, Wilm's tumor, hepatomas, colorectals cancer, brain tumors; mycosis fungoides, Hodgkins lymphoma, polycythemia Vera, chronic granulocytic leukemia, lymphomas, oat cell sarcoma, etc.
- the subject composition will be administered to a tumor to provide a cytotoxic amount of drug at the tumor site.
- the amount of cytotoxic drug administered to the tumor site will generally range from about 0.1 to 500, more usually about 0.5 to 300 mg/kg of host, depending upon the nature of the drug, size of tumor, and other considerations.
- the vasoconstrictive agents will generally be present in from 1 to 50 weight percent of the therapeutic agent. In view of the wide diversity of tumors, nature of tumors, effective concentrations of drug, relative mobility and the like, a definitive range cannot be specified. With each drug in each tumor, experience will provide an optimum level.
- One or more administrations may be employed, depending upon the lifetime of the drug at the tumor site and the response of the tumor to the drug. Administration may be by syringe, catheter or other convenient means allowing for introduction of a flowable composition into the tumor. Administration may be every three days, weekly, or less frequent, such as biweekly or at monthly intervals.
- Illustrative of the manner of administration according to this invention would be administration of cis-diamino dichloro platinum.
- Drug concentrations in the matrix may vary from 0.01 to 50 mg/ml. Injection may be at one or more sites depending on the size of the lesion. Needles of about 1-2 mm diameter are convenient. For multiple injection templates with predrilled holes may be employed. The drug dose will normally be less than 100 mg/m 2 of patient.
- compositions provide therapeutic gain with tumors greater than 100 mm 3 , more particularly, greater than 150 mm 3 , in volume.
- the subject method is also found to reduce local inflammation as a result of the drug administration. Therefore, local or adjacent tissues is less likely to be affected by the drug. Furthermore, due to the low migratory level of the drug from the site of placement, higher drug dosages can be administered to the site without adverse affects to normal tissue distant from the placement site or to lymphocytes.
- the subject method finds advantage in conjunction with other forms of therapy.
- the lesions may be irradiated prior and/or subsequent to matrix administration. Dose rates may vary from about 20 to 250 rad/min, usually 50 to 150 rad/min, depending on the lesion, period of exposure, and the like.
- Hyperthermia may be used as an adjunctive treatment. Treatment will usually involve heating up to about and including 43° for about 5 to 100 min.
- a transplantable experimental murine fibrosarcoma (2 ⁇ 10 5 RIF-1 cells) was grown intradermally in the flank of 5 month old female C3H mice (Bantin and Kingman, Fremont, CA).
- Cis-diamine dichloroplatinm (II) (cis-Pt) (Sigma Chemical Co., St. Louis, MO.) was dissolved in sterile saline at concentrations of 0.8, 1.6 and 3.2 mg/ml and mixed 1:1 with bovine collagen (BC) (36 mg/ml) in PBS 20 mM phosphate, 140 mM NaCl (Collagen Corp., Palo Alto, CA).
- 5-fluorouracil (Sigma Chem. Co., St Louis, Mo.) with and without epinephrine (Sigma) suspended in saline by sonication (60 mg/ml) and mixed 1:1 with bovine collagen (BC) (Collagen Corp., Palo Alto, CA) (36 mg/ml) or normal saline.
- BC bovine collagen
- the subjects were 25 gm 12 week-old female C3H/He mice (Bantin and Kingman, Fremont, CA) bearing the transplatable experimental murine fibrosarcoma propagated intradermally as previously described.
- mice were assigned randomly to the following groups (4-6 mice per group): (1) untreated controls; (2) 5-FU (100 mg/kg), i.p., 0.1 ml/mouse; (3) 5-FU (100 mg/kg), i.t., 0.1 ml/tumor; (4) 5-FU-BC (100 m.g 5-FU/kg dispersed in BC (18 mg/ml)), i.t., 0.1 ml/tumor, 5-FU-EPI-BC (100 mg 5-FU/kg) 5 mg EPI/kg dispersed in BC (18 mg/ml), i.t., 0.1 ml/tumor.
- groups 4-6 mice per group: (1) untreated controls; (2) 5-FU (100 mg/kg), i.p., 0.1 ml/mouse; (3) 5-FU (100 mg/kg), i.t., 0.1 ml/tumor; (4) 5-FU-BC (100 m.g 5-FU/kg dispersed in BC (18 mg/ml)),
- doxorubicin-HCl (Adriamycin) was studied using the above-described protocol.
- the adriamycin in distilled water (4.45 mg/ml) was mixed with 36 mg/ml bovine collagen (BC) 1:1 to yield a composition ratio of 2.25 mg adriamycin:18 mg BC/ml.
- Intraperitoneal injection of 15 mg/kg of adriamycin was lethal to 75% of the mice, while intratumoral injection was found to be non-toxic.
- VCR vincristine
- mice bearing a single experimental tumor produced as previously described were treated at weekly intervals with formulations containing 5-fluorouracil (50 mg/kg); bovine collagen BC (Collagen Corp., Palo Alto, CA); epinephrine (Sigma Chemical Co., St. Louis, MO); and PBS. WBC's were determined on Day 4 following each treatment cycle and skin reaction on Day 3 after each treatment cycle. Treatment was discontinued for all grops when 3 of 4 experiment groups reach 4 ⁇ initial tumor volume. When tumors reached a volume of 150 mm 3 the mice were randomly assigned to the following groups:
- 5-FU-PBS i.p.
- 5-FU 23 mg/ml
- PBS 0.1 ml injected/mouse i.p.
- 5-FU-BC i.t.
- 5-FU 23 mg/ml
- bovine collagen 36 mg/ml
- 5-FU-BC-epi i.t. 5-FU (23 mg/ml) was combined 1:1 with a bovine collagen (36 mg/ml) containing epinephrine (2.4 mg/ml); 0.1 ml injected i.t.
- 5-FU Sigma Chemical Co., St. Louis, MO
- bovine collagen BC Collagen Corp., Palo Alto, CA
- bovine fibronogen 95% clottable, Sigma
- bovine thrombin 2000NIH units/mg, Sigma
- Ringer's Solution For Injection RFI, Abbott Labs., North Chicago, IL
- Fibrinogen 30 mg/ml; fibrinogen (60 mg/ml) dispersed 1:1 with RFI containing 10 ⁇ l thrombin (1 NIH unit of activity/ml); 0.1 ml i.t.
- 5-FU-Fibrinogen 5-FU (36 mg/ml) combined 1:1 with the fibrinogen preparation described in 2 above, 0.1 ml i.t.
- 5-FU-BC-Fibrinogen 5-FU (36 mg/ml) combined 1:1 with a fibrinogen-BC preparation consisting of fibrinogen (30 mg/ml); BC (36 mg/ml) dispersed in RFI containing 1 NIH unit of thrombin activity/ml, 0.1 ml i.t.
- the evidence for reduced systemic exposure is apparent from the lack of immunosuppression, the relative absence of tumor regression on the contralateral uninjected tumor, and by the relative lack of untoward effect on overlaying normal tissue.
- Tumor bearing mice were irradiated in lead jigs exposing only the tumor and overlying skin with a 250 kVp X-ray machine at a dose rate of 120 rad/min.
- the tumors of the treated and untreated mice were measured three times per week and assayed for regrowth delay and skin reactions as previously described.
- the tumor bearing mice were heated in a precision water bath with 30 gauge thermistor thermometry ( ⁇ 0.2° C.).
- the tumors of the treated and untreated mice were measured three times per week and assayed for regrowth delay as previously described.
- improved neoplastic therapy is achieved by applying to an oncogenic lesion a composition comprising a chemotherapeutic drug composition, by itself or in combination with a vasoconstrictive agent uniformly dispersed in a collagenous aqueous dispersion and introducing the viscous amorphous mixture into the lesion.
- a composition comprising a chemotherapeutic drug composition, by itself or in combination with a vasoconstrictive agent uniformly dispersed in a collagenous aqueous dispersion and introducing the viscous amorphous mixture into the lesion.
- the drug pharmacokinetics are modified, due to modifications of the drug and/or interactions with the collagen, providing for a low level of the drug in the circulating blood.
- the lifetime of the drug can be extended due to protection by the collagenous material, reducing the rate of metabolic inactivation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Treatment of cellular disorders involving abnormal solid cellular growths involves introduction of cytotoxic reagents dispersed in a physiologically acceptable proteinaceous matrix into the solid cellular growth or area of an existing or removed solid cellular growth. Enhanced effectiveness of the drug is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Other drugs may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.
Description
This is a continuation-in-part application of abandoned application Ser. No. 615,008, filed May 29, 1984, which disclosure is incorporated herein by reference.
1. Field of the Invention
The treatment of many cellular disorders, for example, tumors, involves the use of cytotoxic drugs. These drugs exert their activity in a variety of ways, usually interfering with a cellular function essential for the replication and/or viability of the cell. In many, if not most, instances, the drug is not specific for the unnatural cell, but rather tends to exert its effectiveness due to the more rapid proliferation of the abnormal cell, as compared to normal cells. While many organs of the body of a mammalian host regenerate cells rather slowly, there are also other organs, particularly bone marrow, which involves rapid proliferation of stem cells. Therefore, the cytotoxic agents not only can detrimentally affect the slowly regenerating cells, but also have a particularly pernicious effect on the immune system.
Despite the many disadvantages and side effects of employing the strongly cytotoxic drugs, they have found extensive application, because they have provided positive results. However, there is substantial interest in being able to employ the drugs in a manner which directs their activity toward the abnormal cells, in an effort to protect sensitive normal cells, both in the vicinity of and distant from the abnormal cell growth, from the harmful effects of the drug.
2. Description of the Prior Art
U.S. Pat. Nos. 4,322,398; 4,347,234, 4,349,530; and 4,391,797 describe implants and controlled release of drugs. Implantation of drugs in lesions is described in Maugh, Science (1981) 212:1128-1129; Macek et al., Abstracts of Immunology, 4109, p. 1053, Miyata et al., Cancer Research (1983) 43:4670-4675; McLaughlin et al., Cancer Research (1978) 38:1311-1316; and Bier et al., Cancer (1979) 44:1194-1200.
Abnormal solid cellular growth, particularly tumors, or adjacent tissue that may contain tumor cells, are treated by injecting into the abnormal growth area or tissue suspected of containing tumor cells a sufficient mount of a cytotoxic drug dispersed in a stable flowable proteinaceous matrix. The resulting matrix substantially inhibits the migration of the drug from the site of injection, so as to maintain the primary effect of the drug in the region of injection. Migration can be further inhibited by the use of physiologically acceptable materials which enhance the binding of the drug to the matrix or which modify cellular properties or physiological responses to further regionalize the placement of drug at the injection site.
Novel methods and compositions are provided for the chemotherapeutic treatment of solid abnormal tumors, cellular growth, or particularly, adjacent tissues which may contain abnormal tumor cells. The method employs a substantially uniform dispersion of a chemotherapeutic drug in a concentrated dispersion of a physiologically acceptable matrix, particularly a protein such as collagen, fibrinogen, or a derivative thereof, or other high molecular weight physiologically acceptable biodegradable composition, dispersed in a minor amount of a physiologically acceptable aqueous medium. The resulting amorphous mass is injected into the lesion, e.g., tumor, or lesion area, e.g., adjacent tissue, or in those situations where the minor has been removed, tissue adjacent to the previously removed tumor. The proteinaceous matrix is flowable for injection, but provides for stable placement, once injected into the tissue. That is, once injected the proteinaceous matrix adheres to the tissue and does not migrate significantly. The treatment may be employed with various solid tumors, including carcinomas and sarcomas. After injection, the drug is released into the immediate environment, so as to prevent substantial transportation of the drug to other sites, where its cytotoxic effect is undesirable. Thus, the circulating blood level of the drug remains low. In this way an enhanced therapeutic gain is achieved, that is, the cytotoxic effect on malignant cells is greater as compared to susceptible normal cells.
Illustrative of the various diseased states or therapeutic modes in which the subject invention may find application are: (1) Neoplasms in which local recurrence is typical and drug bioavailability is compromised, e.g., brain; (2) tumors in which suspected neoplastic cells remain in the tumor bed following surgical resection, e.g., breast; (3) tumors which are poor candidates for surgical or radiation management, e.g., head, neck, prostate, etc.; (4) adjunctive tumor therapy in combination with physical or non-chemical treatments, e.g., radiation and/or hyperthermia; (5) hyperproliferative diseases refractory to conventional therapy, e.g., psoriasis; (6) concurrent with systemic chemotherapy; (7) concurrent with systemic rescue, e.g., methotrexate, plus collagen matrix intra-tumorally, leucovorin i.v.
The subject compositions are amorphous, injectable and viscous, so as to substantially retain a localized position without significant flow from the site of administration. The compositions can flow under moderate pressure, but will not move significantly after being positioned at a particular site. The protein will be capable of binding the agents covalently or non-covalently, without preventing their therapeutic effect, while retaining the active agents at the site of introduction or retarding transfer of the active agents present from the site of introduction.
Preferably, the composition will be comprised of a significant amount of the matrix to provide the desired composition characteristics. The matrix may be comprised of individual or in combination peptides or proteins, e.g., structural proteins such as collagen and fibrinogen, or albumin or other protein which provides for stable placement, or combinations thereof. Of particular interest is collagen, fibrinogen or derivative thereof.
Proteinaceous compositions having at least about 5 weight percent, preferably at least about 10 weight percent, and up to 50 weight percent or more, are of particular interest when used in combination with thrombin or its enzymatic equivalent. In this way fibrinogen is enzymatically modified to fibrin to enhance the non-migratory property of the composition while forming a matrix of fibrils to further stabilize the composition.
The thrombin may be mixed with fibrinogen containing proteinaceous composition from a time immediately prior to use or shortly after injection. The amount of thrombin of about 1 to 1000 IU/mg employed will generally range from about 0.1 to 10 weight percent of the fibrinogen present, depending upon the time of use, the rate desired for solid matrix formation, the amount of other components, the effect of the drug on thrombin activity, and the like.
In addition to the matrix material will be one or more chemotherapeutic drugs, and a physiologically acceptable aqueous medium in which the proteinaceous composition is dispersed and the drug may be dissolved, dispersed, or complexed with the collagen. Other materials are preferably present to enhance the beneficial properties of the subject composition.
The proteinaceous, particularly collagenous or fibrinogen-containing, material which is used may be derived from any mammalian host source, such as bovine, porcine or human, or may be prepared, as available, by other techniques, e.g. recombinant DNA techniques. The collagen employed may be natural collagen or may be modified, such as tropocollagen, atropocollagen, or the like. The collagen may be non-immunogenic, immunogenic, or only slightly immunogenic.
Various methods of preparing collagen or derivatives thereof in purified form for administration to a mammalian host are known in the literature. These methods may be found in such patents as U.S. Pat. No. 3,949,073 and references cited therein. Of interest is bovine collagen which is purified and is obtained from young cows or calves. Purification will normally involve dispersion or precipitation from various media, e.g., dilute acetic acid. In some situations xenogeneic collagen is employed to enhance an immunogenic response in the area of injection or immunogenic adjuvants may be employed.
A wide variety of chemotherapeutic drugs may be employed individually or in combination. The drugs may be bound or unbound to the matrix, through such binding as complexation, salt formation, coordination complexes, or the like, but any binding should not result in significant diminution of the physiological activity of the drug. Various drugs may be employed which are used in chemotherapy and act as alkylating agents, enzyme inhibitors, proliferation inhibitors, lytic agents, DNA synthesis inhibitors, membrane permeability modifiers, DNA intercalators, antimetabolites, or the like. Illustrative drugs include chlorambucil, melphalan, busulfan, carmustine, lomustine, streptozotocin, thiotepa, decarbazine methotrexate, 5-fluorouracil, cytarabine, azaribine mercaptopurine, thioguanine, vinblastine, vincristine, antinomycin D, adriamycin, bleomycin, mithramycin, mitomycin C, L-asparaginase, cisplatin, procarbazine, prednisone, prednisilone, triamicinolone, testosterone, estrogen, insulins, and hydroxyurea. See Carter and Livingston, Drugs Available to Treat Cancer. In Principles of Cancer Treatment (Carter et al., eds.) Chapter 10, pp. 111-145, 1982, McGraw-Hill, Inc., N.Y. The drugs should not form non-enzymatically-labile bonds with the matrix material resulting in the loss of their therapeutic effect.
The drugs may be used individually or in combination, depending upon the nature of the drug, the tumor, and whether cooperative action is pharmacologically indicated. The drug composition can be further modified, by modifying the drug, particularly by bonds which allow for enzymatic cleavage, e.g., hydrolysis, or by introducing materials into the composition which will aid in the maintenance of the retention of the drug at the site of introduction.
Various techniques can be used for diminishing drug migration, for example, by coupling the drug with specific ligands, such as lipids, phospholipids, peptides, amino acids, sugars, or the like. These modifications will depend upon the individual drug, varying the solubility of the drug in the aqueous medium and providing for covalent or non-covalent interactions with the protein. In addition, various physiologically acceptable bulking agents or concentrating agents may be employed, which serve to provide for drug and protein interactions, with resulting reduction in the rate of drug release. Illustrative materials include inorganic substances, such as hydroxyapatite and organic substances such as carbohydrates, e.g, agarose and cellulose.
Other drugs for use in combination with the chemotherapeutic agents are drugs which retard the diffusion away of the chemotherapeutic agent, so as to reduce physiological insult and enhance therapeutic gain. Of particular interest are agents which restrict regional vasculature, either as to growth and/or passage opening, e.g., vasoconstrictive or sympathomimetic agents. These agents may include catechol amines, e.g., epinephrine and nor-epinephrine ergot alkaloids, prostaglandins, angiotensin or the like. Other agents for affecting tissue architecture include enzymes which can injure the stroma, such as the peptidases papain, chymopapain, trypsin, amylase, collagenase and chymotrypsin. Or, agents affecting cellular permeability may be employed, such as non-ionic detergents, e.g., Tween 80, amphotericin B, dimethylsulfoxide and anaesthetics, such as procaine.
In addition, the drug(s) can be employed encapsulated in liposomes or other controlled rate release compositions, which are included in the proteinaceous composition, so as to provide for separate and distinct rates of release of the drug. In this way, multiphasic compositions can be prepared, so as to provide for sustained release of the drug over long periods of time. Formation of liposomes with inclusion of various materials is described in Papahadjopoulos (1978) Annals of the N.Y. Academy of Science, 308; Gregoriadis and Allison (1980) Liposomes in Biological Systems, John Wiley and Sons, Leserman et al., Nature (1981) 293:226-228; Barhet et al, Supramol. Struct. Cell Bio. Chem. (1981) 16:243-258; and Heath et al., Science (1980) 255:8015-8018. Alternatively, other methods of encapsulation can be employed where the drug is encapsulated in a biodegradable substance, where the rate of release is related to the thickness of the biodegradable coat.
Besides using xenogeneic collagen, other materials may be included to enhance an immunogenic response,
e.g., proliferation and invasion of macrophage, helper T-cells, etc. Illustrative adjuvants include Corynebacterium parvum, Bacillus Calmette-Guerin cell wall or cell wall skeleton preparations, Mycobacterium bovis strain, etc. See Miyata et al., Cancer Res. (1983) 43:4670-4675; Bier et al., Arch. Otorhinolaryngol, (1982) 236:245-255; and Mehanjhlin et al., Cancer Res. (1978) 38:1311-1316, whose relevant disclosure is incorporated herein by reference.
For enhancing cytotoxic activity various adjuvant materials may be incorporated into the matrix, such as radioactive pellet, e.g., radionuclides Technicium or Iridium; radiation sensitizers, e.g., misonidazole; repair inhibitors, e.g., methylated xanthines; bioreductive agents, which are activated only in hypoxic cells; immunomodifiers, such as interferons, lymphokines, such as interleukin-2; tumor growth inhibitors, such as tumor necrosis factor, tumor growth factor-β, etc., and/or angiographic contrast media.
As already indicated, the ratio of dry materials in the composition may vary widely. However, the amount of protein matrix material will usually be not less than 30% and not greater than about 95%, generally ranging from about from 40% to 90%, more usually ranging from about 50% to 90% by weight. Of this, preferably 10 to 100% will be collagen and/or fibrinogen. The chemotherapeutic drug(s) will normally be a liquid or solid, or provided in solid form and a generally range from at least about 0.1% by weight to up to about 50% by weight, more usually being from about 1% to 50% by weight, generally being from about 1% to 45% by weight of the proteinaceous material.
Other ancillary additives or agents will vary in total amount from about 0.005 to 15, usually from about 0.01 to 10 weight percent of the dry weight of the total composition.
The composition is uniformly dispersed in a physiologically acceptable aqueous medium, such as saline, phosphate buffered saline, distilled water, etc. The aqueous medium will be sufficient to provide for an amorphous dispersion capable of flowing under mild pressure. Usually, the liquid aqueous medium will be at least 90 weight percent of the entire composition, more usually at least 95% weight percent, and not more than about 99.8 weight percent, usually not more than about 99.5 weight percent, so as to provide a flowable mixture. The amount will vary depending upon the nature of the drug(s), the nature of the matrix material, the presence of other materials, and the like. The concentration of protein in the aqueous medium will range from about 5 to 75 mg/ml.
In addition to the major components, a number of minor components may also be included for a variety of purposes. These agents will for the most part impart properties which protect the stability of the composition, control the pH, or the like. Illustrative agents include phosphate or acetate buffers, methyl or propyl paraben, polyethylene glycols, etc. These agents generally will be present in less than about 2 weight percent of the total composition, usually less than about 1 weight percent, and individually may vary from about 0.001 weight percent to about 1 weight percent.
As already indicated, in some instances the drug will be encapsulated particularly in liposomes. Liposomes are prepared from a variety of lamellar-forming lipids including phospholipids, e.g., phosphatidylcholine, phosphatidylethanolamine, etc., gangliosides, sphingomyelins, steroids, e.g., cholesterol, etc. Usually, the weight of the lipids in relation to the weight of drug will range from 1 to 5 L of entrapped drug per mole of amphiphatic lipid.
The composition can be prepared by combining the various components in a sterile environment. The matrix will be provided in a convenient form, usually admixed with at least a portion of the total aqueous medium to be employed. The composition will be sufficiently workable that upon admixture of the other agents a uniform dispersion can be obtained. When collagen or derivative thereof is used, the collagenous material will normally be provided as a uniform dispersion of collagen fibrils in an aqueous medium, where the collagenous material will be from about 5 mg/ml to not more than 100, usually not more than 75 mg/ml. The drug may then be added to the collagenous dispersion with agitation to ensure the uniform dispersion of the drug in the resulting mixture. Other materials, as appropriate, may be added concomitantly or sequentially. After ensuring the uniform dispersion of the various components in the mixture, the mixture may be sterilized and sealed in appropriate container.
Sterilization will usually be achieved using aspetic conditions.
The subject composition can be used in the treatment of a wide variety of neoplastic lesions. Illustrative tumors include carcinomas, sarcomas and melanomas, such as basal cell carcinoma, squamous cell carcinoma, melanoma, soft tissue sarcoma, solar keratoses, Kaposi's sarcoma, cutaneons malignant lymphoma, Bowen's disease, Wilm's tumor, hepatomas, colorectals cancer, brain tumors; mycosis fungoides, Hodgkins lymphoma, polycythemia Vera, chronic granulocytic leukemia, lymphomas, oat cell sarcoma, etc.
The subject composition will be administered to a tumor to provide a cytotoxic amount of drug at the tumor site. The amount of cytotoxic drug administered to the tumor site will generally range from about 0.1 to 500, more usually about 0.5 to 300 mg/kg of host, depending upon the nature of the drug, size of tumor, and other considerations. The vasoconstrictive agents will generally be present in from 1 to 50 weight percent of the therapeutic agent. In view of the wide diversity of tumors, nature of tumors, effective concentrations of drug, relative mobility and the like, a definitive range cannot be specified. With each drug in each tumor, experience will provide an optimum level. One or more administrations may be employed, depending upon the lifetime of the drug at the tumor site and the response of the tumor to the drug. Administration may be by syringe, catheter or other convenient means allowing for introduction of a flowable composition into the tumor. Administration may be every three days, weekly, or less frequent, such as biweekly or at monthly intervals.
Illustrative of the manner of administration according to this invention would be administration of cis-diamino dichloro platinum. Drug concentrations in the matrix may vary from 0.01 to 50 mg/ml. Injection may be at one or more sites depending on the size of the lesion. Needles of about 1-2 mm diameter are convenient. For multiple injection templates with predrilled holes may be employed. The drug dose will normally be less than 100 mg/m2 of patient.
The subject method finds particular advantage with tumors or lesions which are clinically relevant. The compositions provide therapeutic gain with tumors greater than 100 mm3, more particularly, greater than 150 mm3, in volume.
The subject method is also found to reduce local inflammation as a result of the drug administration. Therefore, local or adjacent tissues is less likely to be affected by the drug. Furthermore, due to the low migratory level of the drug from the site of placement, higher drug dosages can be administered to the site without adverse affects to normal tissue distant from the placement site or to lymphocytes.
The subject method finds advantage in conjunction with other forms of therapy. The lesions may be irradiated prior and/or subsequent to matrix administration. Dose rates may vary from about 20 to 250 rad/min, usually 50 to 150 rad/min, depending on the lesion, period of exposure, and the like. Hyperthermia (heat) may be used as an adjunctive treatment. Treatment will usually involve heating up to about and including 43° for about 5 to 100 min.
In order to demonstrate the subject invention, the following investigations were performed. A transplantable experimental murine fibrosarcoma (2×105 RIF-1 cells) was grown intradermally in the flank of 5 month old female C3H mice (Bantin and Kingman, Fremont, CA). Cis-diamine dichloroplatinm (II) (cis-Pt) (Sigma Chemical Co., St. Louis, MO.) was dissolved in sterile saline at concentrations of 0.8, 1.6 and 3.2 mg/ml and mixed 1:1 with bovine collagen (BC) (36 mg/ml) in PBS 20 mM phosphate, 140 mM NaCl (Collagen Corp., Palo Alto, CA). Doses of 2, 4 and 8 mg/kg host of cis-Pt were delivered in 0.1 ml of the collagenous drug mixture to the center of the tumor growing in the flank (intratumorally, i.t.), and the tumor measured. The growth of a second uninjected tumor on the opposing flank of the same mouse was also measured. In addition, cis-Pt dissolved in PBS without collagen was administered intraperitoneally (i.p.) to other tumor-bearing mice (4 tumors/group) to monitor the effects on tumor growth of the drug without collagen. Furthermore, the effect of bovine collagen on tumor growth was also studied by injection of 0.1 ml of collagen, (18 mg/ml) into the experimental fibrosarcomas, as previously described. The growth of the tumors was monitored three times per week by caliper measurements of three perpendicular diameters of the tumor and calculating tumor volume from the formula
V=π/6×D.sub.1 ×D.sub.2 ×D.sub.3.
The following Tables 1 and 2 indicate the results.
TABLE 1 ______________________________________ Effect of cis-Pt-BC Fibrosarcoma Regrowth Delay Treatment Route of cis-Pt Dose # Tumors Regrowth Group Administration (mg/kg) Measured Delay* (Days) ______________________________________ Untreated i.p. -- 4 6.3 ± 0.3** (PBS) cis-Pt i.p. 2 4 7.2 ± 0.1 cis-Pt-BC i.t. 2 4 9.0 ± 1.1 cis-Pt i.p. 4 6 9.1 ± 0.7 cis-Pt-BC i.t. 4 4 9.9 ± 0.3 cis-Pt i.p. 8 6 9.9 ± 1.0 cis-Pt-BC i.t. 8 4 12.7 ± 1.2 ______________________________________ *Regrowth Delay determined as the time (days) for tumors to grow to four times their initial treatment volume (150 mm.sup.3). Increasing values indicate enchanced therapeutic effect. **Mean ± S.E.
TABLE 2 ______________________________________ Effect of cis-Pt-BC on the Growth of Uninjected Contralateral Fibrosarcoma Treatment Route of cis-Pt Dose # Tumors Regrowth Group Administration (mg/kg) Measured Delay* (Days) ______________________________________ Untreated i.p. -- 4 6.3 ± 0.3** (PBS) cis-Pt i.p. 2 4 7.2 ± 0.1 cis-Pt i.t. 2 4 9.5 ± 0.5 uninjected -- -- 4 9.3 ± 1.2 contra cis-Pt-BC i.t. 2 4 9.0 ± 1.1 uninjected -- -- 4 7.2 ± 0.4 contra cis-Pt i.p. 4 6 9.1 ± 0.7 cis-Pt i.t. 4 4 10.3 ± 0.7 uninjected -- -- 4 8.9 ± 0.7 contra cis-Pt-BC i.t. 4 4 9.9 ± 0.3 uninjected -- -- 4 7.4 ± 0.6 contra cis-Pt i.p. 8 6 9.9 ± 1.0 cis-Pt i.t. 8 4 11.5 ± 0.04 uninjected -- -- 4 9.9 ± 0.9 contra cis-Pt-BC i.t. 8 4 12.7 ± 1.3 uninjected -- -- 4 9.0 ± 1.1 contra ______________________________________ *Regrowth Delay determined as the time (days) for tumors to grow to four times their initial treatment volume (150 mm.sup.3). **Mean ± S.E.
In the next study 5-fluorouracil (5-FU) (Sigma Chem. Co., St Louis, Mo.) with and without epinephrine (Sigma) suspended in saline by sonication (60 mg/ml) and mixed 1:1 with bovine collagen (BC) (Collagen Corp., Palo Alto, CA) (36 mg/ml) or normal saline. The subjects were 25 gm 12 week-old female C3H/He mice (Bantin and Kingman, Fremont, CA) bearing the transplatable experimental murine fibrosarcoma propagated intradermally as previously described.
When the tumors reached a volume of 150 mm3, the mice were assigned randomly to the following groups (4-6 mice per group): (1) untreated controls; (2) 5-FU (100 mg/kg), i.p., 0.1 ml/mouse; (3) 5-FU (100 mg/kg), i.t., 0.1 ml/tumor; (4) 5-FU-BC (100 m.g 5-FU/kg dispersed in BC (18 mg/ml)), i.t., 0.1 ml/tumor, 5-FU-EPI-BC (100 mg 5-FU/kg) 5 mg EPI/kg dispersed in BC (18 mg/ml), i.t., 0.1 ml/tumor.
On day four post-treatment, white blood cells (wbc) were counted by sampling blood from the tail, dilution in Turk's solution and counting in a hemocytometer. On day eight post-treatment, skin reaction is overlying tissue was graded for untoward response.
The following Table 3 indicates the results.
TABLE 3 ______________________________________ Effect of 5-Fluorouracil (5-FU) (100 mg/kg) - Bovine Collagen (BC) ± Epinephrine (EPI) (5 mg/kg) on Tumor Growth and Normal Tissue Response** Untreated Experimental Tumor Contralateral White Blood Group (4-6 Regrowth Regrowth Cells/mm.sup.3 Skin mice/group) Delay (days) Delay (days) (×10.sup.3) Reaction* ______________________________________ Untreated 6.3 ± 0.7*** 6.3 ± 0.7 7.9 ± 1.6 1.0 ± 0.4 Controls 5-FU i.p. 13.1 ± 1.4 13.1 ± 1.4 4.5 ± 0.6 0.7 ± 0.4 5-FU i.t. 14.5 ± 0.9 11.1 ± 0.6 3.5 ± 0.5 0 5-FU-BC i.t. 15.1 ± 3.3 8.6 ± 0.5 5.4 ± 2.2 1.3 ± 0.5 5-FU-EPI- 17.7 ± 1.7 12.5 ± 1.2 5.0 ± 1.5 0 BC i.t. ______________________________________ *Skin reaction. Evaluation of the skin overlying the tumor on Day 8 post injection. The skin reaction is scored as follows: 0 = no effect; 1 = superficial inflammation; 2 = scab; 3 = ulcer. **5FU-EPI i.t. was lethal to the mouse. ***mean ± S.E.
In the next study doxorubicin-HCl (ADM) (Adriamycin) was studied using the above-described protocol. The adriamycin in distilled water (4.45 mg/ml) was mixed with 36 mg/ml bovine collagen (BC) 1:1 to yield a composition ratio of 2.25 mg adriamycin:18 mg BC/ml. Intraperitoneal injection of 15 mg/kg of adriamycin was lethal to 75% of the mice, while intratumoral injection was found to be non-toxic.
The following Table 4 indicates the results.
TABLE __________________________________________________________________________ Effect of Adriamycin (ADM) (15 mg/kg) - Bovine Collagen (BC) on Acute Animal Toxicity, Tumor Growth and Normal Tissue Response Animal Tumor Regrowth Delay.sup.2 White Blood Experimental Group Survival.sup.1 Treated/Contralateral.sup.3 Cells/mm.sup.3 4 Skin (4-6 mice/group) (%) (days) (×10.sup.3) Reaction.sup.5 __________________________________________________________________________ Untreated Controls 100 5.4 ± 0.2/5.4 ± 0.2 10.2 ± 1.7 1.3 ± 0.4 Free ADM i.p. 25 10.6 ± 1.6/10.6 ± 1.6 3.4 1.5 ± 0.5 Free ADM i.t. 100 13.7 ± 1.7/8.3 ± 0.75 4.1 ± 0.69 2.0 ADM-BC i.t. 100 10.6 ± 0.9/7.8 ± 1.3 6.8 ± 0.71 1.8 ± 0.2 __________________________________________________________________________ .sup.1 Animal survival after injection ofADM 15 mg/kg. Deaths usually resulted within 2 days after injection. .sup.2 Tumor Regrowth Delay (RD). Time (days) required for tumors to grow to 3× its original treatment volume (˜150 mm.sup.3). Increasing RD indicate increased tumor cell killing. .sup.3 Contralateral Tumor RD (CRD). Time (days) required for untreated contralateral tumors to grow to 3× its original treatment volume (˜150 mm.sup.3). Decreasing RD indicate enhanced regionalization of drug injected when compared to RD. .sup.4 White Blood Cells measured onDay 4 post injection by sampling fro the tail of treatment mice. .sup.3 Skin reaction. Evaluation of the skin overlying the tumor on Day 8 post injection. The skin reaction is scored as follows: 0 = no effect; 1 = superficial inflammation; 2 = scab; 3 = ulcer;
In the next study vincristine (VCR) was dissolved in saline (0.6 mg/ml) by sonication and mixed 1:1 with bovine collagen (36 mg/ml). Otherwise, the procedure was the same. The following Table 5 indicates the results.
TABLE 5 ______________________________________ Effect of Vincristine (VCR) (2 mg/kg) - Bovine Collagen (BC) on Tumor Growth and Normal Tissue Response Untreated Experimental Tumor Contralateral White Blood Group (4-6 Regrowth Regrowth Cells/mm.sup.3 Skin mice/group) Delay (days) Delay (days) (×10.sup.3) Reaction ______________________________________ Untreated 5.3 ± 0.2 5.3 ± 0.2 10.2 ± 1.7 1.3 ± 0.4 Controls VCR i.p. 10.6 ± 2.0 10.6 ± 2.0 7.4 ± 1.3 0.6 ± 0.4 VCR-BC i.t. 10.2 ± 1.3 7.6 ± 1.1 9.4 ± 2.9 1.2 ± 0.5 ______________________________________
In the next study a combination of bleomycin sulfate (Sigma Chemical Co., St. Louis, MO) (15 mg/kg) and epinephrine (5 mg/kg) employed in a bovine collagen composition were evaluated for antitumor effect in the transplantable experimental murine fibrosarcoma model previously described. The following Table 6 provides the results.
TABLE 6 ______________________________________ Effect of Bleomycin Sulfate (BLM) (15 mg/kg) - Bovine Collagen (BC) ± Epinephrine (EPI) (5 mg/kg) on Tumor Growth and Normal Tissue Response Untreated Experimental Tumor Contralateral White Blood Group (4-6 Regrowth Regrowth Cells/mm.sup.3 Skin mice/group) Delay (days) Delay (days) (×10.sup.3) Reaction ______________________________________ Untreated 6.3 ± 0.7* 6.3 ± 0.7 7.9 ± 1.6 1.0 ± 0.4 Controls BLM i.p. 7.5 ± 0.9 7.5 ± 0.9 10.8 ± 1.8 1.5 ± 0.3 BLM i.t. 8.9 ± 0.6 7.0 ± 0.7 7.0 ± 1.3 2.3 ± 0.3 BLM-BC i.t. 9.4 ± 0.9 7.2 ± 0.1 8.0 ± 1.5 1.8 ± 0.3 BLM-EPI- 9.7 ± 0.6 7.2 ± 1.2 23.3 ± 10.7 1.5 ± 0.5 BC i.t. ______________________________________ *mean ± S.E.
In another experiment the curative potential of drug matrix formulations was evaluated in the experimental murine fibrosarcoma model. Briefly, female C3H/He mice bearing a single experimental tumor produced as previously described were treated at weekly intervals with formulations containing 5-fluorouracil (50 mg/kg); bovine collagen BC (Collagen Corp., Palo Alto, CA); epinephrine (Sigma Chemical Co., St. Louis, MO); and PBS. WBC's were determined on Day 4 following each treatment cycle and skin reaction on Day 3 after each treatment cycle. Treatment was discontinued for all grops when 3 of 4 experiment groups reach 4×initial tumor volume. When tumors reached a volume of 150 mm3 the mice were randomly assigned to the following groups:
1. Untreated controls
2. 5-FU-PBS i.p.; 5-FU (23 mg/ml) was combined 1:1 with PBS; 0.1 ml injected/mouse i.p.
3. 5-FU-PBS i.t.; 5-FU (23 mg/ml) was combined 1:1 with PBS; 0.1 ml injected/tumor i.t.
4. 5-FU-BC i.t.; 5-FU (23 mg/ml) was combined 1:1 with bovine collagen (36 mg/ml); 0.1 ml injected i.t.
5. 5-FU-BC-epi i.t.; 5-FU (23 mg/ml) was combined 1:1 with a bovine collagen (36 mg/ml) containing epinephrine (2.4 mg/ml); 0.1 ml injected i.t.
The results are shown in below in Table 7.
TABLE 7 ______________________________________ Effect of 5-Fluorouracil (5-FU 50 mg/kg Administered on Days 0, 8 and 16) - Bovine collagen ± Epinephrine (5 mg/kg) on Tumor Growth and Normal Tissue Tumor Contra- Skin Experimental Regrowth lateral RDWBC Reaction Group 4× (days) 4× (days) D-12 D-8 ______________________________________ Untreated 6.3 ± 1.1 -- 79 ± 13 2.6 ± 0.1 Controls 5-FU-PBS i.p. 10.3 ± 1.3 -- 109 ± 28 1.2 ± 1.1 5-FU-PBS i.t. 14.9 ± 3.8 -- 107 ± 25 1.0 ± 0.6 5-FU-BC i.t. 11.2 ± 4.2 -- 120 ± 21 1.6 ± 0.5 5-FU-BC-EPI i.t. 26.0 ± 1.7 -- 62 ± 6 1.4 ± 0.5 ______________________________________
The results indicate that epinephrine (5 mg/Kg) used as a vascoactive modifier with low dose 5-FM-CM drug-matrix administered intratumorally (i.t.) in three weekly injections enhanced the antitumor effect of 5-FU by a factor of 2-2.5 with respect to i.p. treated minor regrowth delay.
In another experiment the influence of matrix composition on antitumor activity of 5-fluorouracil (100 mg/kg) was evaluated in the experimental murine fibrosarcoma model previously described. 5-FU (Sigma Chemical Co., St. Louis, MO) was combined as described below with bovine collagen BC (Collagen Corp., Palo Alto, CA); bovine fibronogen (95% clottable, Sigma); bovine thrombin (2000NIH units/mg, Sigma) and Ringer's Solution For Injection (RFI, Abbott Labs., North Chicago, IL). When tumors reached a volume of 150 mm3 the mice (Bantin and Kingman, Fremont, CA) were assigned randomly to the following groups, (3-4 mice/group):
1. Untreated controls
2. Fibrinogen 30 mg/ml; fibrinogen (60 mg/ml) dispersed 1:1 with RFI containing 10 μl thrombin (1 NIH unit of activity/ml); 0.1 ml i.t.
3. 5-FU-Fibrinogen: 5-FU (36 mg/ml) combined 1:1 with the fibrinogen preparation described in 2 above, 0.1 ml i.t.
4. 5-FU-BC-Fibrinogen: 5-FU (36 mg/ml) combined 1:1 with a fibrinogen-BC preparation consisting of fibrinogen (30 mg/ml); BC (36 mg/ml) dispersed in RFI containing 1 NIH unit of thrombin activity/ml, 0.1 ml i.t.
The results are summarized in the following Table 8.
TABLE 8 ______________________________________ Effect of Matrix Composition on Activity of 5-Fluorouracil (100 mg/kg) Tumor Experimental RegrowthUntreated Group Delay 4× Contralateral WBC/ Skin 3-4 mice/grp (days)RD 4× (days) mm.sup.3 × 10.sup.3 Reaction ______________________________________ Untreated 6.3 ± 1.1 6.3 ± 1.1 79 ± 13 2.6 ± 0.1 Controls 5-FU-Fib (30 mg/ 11.9 ± 1.7 7.7 ± 0.9 147 ± 38 1.3 ± 0.6 ml) Fib (30 mg/ml) 5.5 ± 0.8 5.9 ± 0.5 276 ± 64 2.0 ± 0.0 5-FU-Fib (15 mg/ 9.1 ± 0.8 8.2 ± 0.6 168 ± 27 2.0 ± 0.0 ml) - BC (18 mg/ ml) ______________________________________
As evidenced from the above results, substantial advantages are obtained in therapeutic gain, both in the presence or absence of ancillary agents, when the therapeutic drugs are formulated as a flowable matrix in collagen and implanted in the lesion. The formulation retains the high chemotherapeutic activity of the chemotherapeutic agent, while substantially reducing the cytotoxic effect on white blood cells and inflammatory activity on adjacent epidermal tissue.
The evidence for reduced systemic exposure is apparent from the lack of immunosuppression, the relative absence of tumor regression on the contralateral uninjected tumor, and by the relative lack of untoward effect on overlaying normal tissue.
In the next experiment 5-fluorouracil-matrix implant in combination with X-rays was evaluated. Single RIF-1 tumors were grown on the back of female C3H mice (12-16 weeks) (Bantin and Kingman, Fremont, CA) as previously described. When the tumors reached volumes of 150 mm3, they were divided into the following groups, (4-6 mice/group):
1. Untreated controls
2. X-rays (1000 rad.) alone
3. Collagen-matrix (CM) i.t. 5 min. before X-rays
4. 5-Fluorouracil (5-FU) (75 mg/Kg) i.p.
5. 5-FU-CM (75 mg/KG) i.t.
6. 5-FU i.p. 5 min before X-rays
7. 5-FU-CM i.t. 5 min before X-rays
Tumor bearing mice were irradiated in lead jigs exposing only the tumor and overlying skin with a 250 kVp X-ray machine at a dose rate of 120 rad/min. The tumors of the treated and untreated mice were measured three times per week and assayed for regrowth delay and skin reactions as previously described.
The results are set forth in the following Table 9:
TABLE 9 ______________________________________ Effect of 5-Fluorouracil (5-FU) (75 mg/Kg) - Collagen Matrix (CM) (30 mg/ml) Intralesional (i.t.) Implants in Conjunction with X-rays (1000 rad) on RIF-1Tumor Regrowth Delay 2× Tumor Regrowth Skin Experimental Group Delay (days) Reaction ______________________________________ Untreated Controls 3.1 ± 0.4 2 5-FU (i.p.) 8.5 ± 1.1 2 5-FU-CM (i.t.) 6.3 ± 0.5 2 X-rays alone 6.9 ± 0.3 2 CM (i.t.) + X-rays 6.0 ± 0.3 2 5-FU (i.p.) + X-rays 12.6 ± 2.8 2 5-FU-CM (i.t.) + X-rays 15.5 ± 0.9 2 ______________________________________
The results indicate that in a combined modality setting intralesional (i.t.) administration of 5-FU-CM in conjunction with X-rays is comparable to X-rays with systemic (i.p.) 5-FU in terms of regrowth delay.
In the next study cis-DDP-matrix (DDP=cis-Pt) implant in combination with hyperthermia was evaluated. Single RIF-1 tumors were grown on the back of female C3H mice as previously described. When the tumors reached volumes of 150 mm3, they were divided into the following groups (4-6 mice/group):
1. Untreated controls
2. Hyperthermia (43° C., 30 min) alone
3. Hyperthermia+collagen-matrix (CM)+epinephrine (epi) (2 mg/Kg)
4. cis-DDP (6 mg/Kg) i.p.
5. cis-DDP-CM-epi (i.t.)
6. cis-DDP (i.p.) 30 min before hyperthermia
7. cis-DDP-CM-epi (i.t.) 30 min before hyperthermia.
The tumor bearing mice were heated in a precision water bath with 30 gauge thermistor thermometry (±0.2° C.). The tumors of the treated and untreated mice were measured three times per week and assayed for regrowth delay as previously described.
The following Table 10 indicates the results:
TABLE 10 ______________________________________ Effect of Local Hyperthermia (43° C. 30 min) on cis-DDP (6 mg/Kg) Collagen Matrix (CM) (30 mg/ml) - Epinephrine (Epi) (2 mg/Kg) Intralesional (i.t.) Implants on RIF-1 Regrowth Delay Tumor Regrowth Delay (2×) Experimental Group (2×) (days) ______________________________________ Untreated Controls 3.5 ± 0.1 Hyperthermia alone 7.9 ± 1.3 Hyperthermia + CM-Epi (i.t.) 8.5 ± 0.5 cis-DDP (i.p.) 6.5 ± 1.5 cis-DDP-CM-Epi (i.t.) 10.0 ± 0.1 cis-DDP (i.p.) 30 min before hyperthermia 8.9 ± 0.8 cis-DDP-CM-Epi (i.t.) 30 min before 21.5 ± 2.3 hyperthermia ______________________________________
The results indicate that local hyperthermia can enhance the effect of collagen matrix associated cis-DDP administered intratumorally. Collagen matrix (CM) with epinephrine (i.t.) alone with hyperthermia did not increase the antitumor effect of hyperthermia.
In accordance with the subject invention, improved neoplastic therapy is achieved by applying to an oncogenic lesion a composition comprising a chemotherapeutic drug composition, by itself or in combination with a vasoconstrictive agent uniformly dispersed in a collagenous aqueous dispersion and introducing the viscous amorphous mixture into the lesion. It is found that by employing the drug-collagenous composition, greatly enhanced localized drug concentration can be achieved. In addition, in view of the significant cytotoxic effects of drugs employed in chemotherapy, systemic exposure is substantially diminished. Therefore, high levels of cytotoxic drugs can be employed at the site of interest, while the remainder of the host is not exposed to significant levels of the drug. In addition, the drug pharmacokinetics are modified, due to modifications of the drug and/or interactions with the collagen, providing for a low level of the drug in the circulating blood. Finally, the lifetime of the drug can be extended due to protection by the collagenous material, reducing the rate of metabolic inactivation.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
Claims (3)
1. A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug .Iadd.or proliferation inhibitor.Iaddend..Badd., wherein when said proteinaceous composition comprises collagen, said collagen is present as a uniform dispersion of collagen fibrils.Baddend.. 2. A composition according to claim 1, wherein said cytotoxic drug is cis-platinum, adriamycin, bleomycin, 5-fluorouracil or vincristine. 3. A .Badd.proteinaceous .Baddend.composition . .. .according to claim 1, having.!..!. .Badd.comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml; from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug or proliferation inhibitor and .Baddend.a vasoconstrictive amount of a vasoconstrictive drug. 4. A composition according to claim 3, wherein said . .. .vasoconstrictor.!..!. .Badd.vasoconstrictive .Baddend.drug is epinephrine or nor-epinephrine. 5. A method for treating a neoplastic .Iadd.or hyperproliferative .Iaddend.lesion or surrounding tissue which comprises:
introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement, consisting essentially . .or.!. .Iadd.of a .Iaddend.physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass including at least one cytotoxic drug .Iadd.or proliferation inhibitor .Iaddend.uniformly dispersed in said composition. .;.!.. .. .:.!..!..Badd.;.Baddend.
whereby said . .. .drug.!..!. .Badd.cytotoxic drug or proliferation inhibitor .Baddend.is slowly released into the . .. .immediate environment.!..!. .Badd.neoplastic or hyperproliferative lesion or surrounding tissue .Baddend.avoiding significant levels of . .. .the drug.!..!. .Badd.said cytotoxic drug or proliferation inhibitor .Baddend.at sites distant from the site of introduction. 6. A method according to claim 5, wherein said proteinaceous composition is a collagen fibril dispersion. 7. A method according to claim 6, wherein said . .. .drug.!..!. .Badd.cytotoxic drug or proliferation inhibitor .Baddend.is at least one of cis-platinum, adriamycin, . .. .5fluorouracil.!..!. .Badd.5-fluorouracil.Baddend., bleomycin, vincristine, or methotrexate. 8. A method according to claim 7, wherein said composition includes a sufficient amount of a . .. .vasoconstrictor.!..!. .Badd.vasoconstrictive drug .Baddend.to constrict capillaries in the vicinity of said lesion. 9. A method according to claim 8, wherein said . .. .vasoconstrictor.!..!. .Badd.vasoconstrictive drug .Baddend.is epinephrine or nor-epinephrine. 10. A method according to claim 7, wherein said . .. .drug.!..!. .Badd.cytotoxic drug or proliferation inhibitor .Baddend.is cis-platinum. 11. A method according to claim 7, wherein said . .. .drug.!..!. .Badd.cytotoxic drug or proliferation inhibitor .Baddend.is
5-fluorouracil. 12. A method according to claim 5, comprising the additional step of treating said lesion . .. .size.!..!. .Badd.site .Baddend.with radiation or heat. .Iadd.13. A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug.Iaddend..Badd., wherein when said proteinaceous composition comprises collagen, said collagen is present as a uniform dispersion of collagen fibrils. .Baddend..Iadd.14. A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a proliferation inhibitor.Iaddend..Badd., wherein when said proteinaceous composition comprises collagen, said collagen is present as a uniform dispersion of collagen fibrils. .Baddend..Iadd.15. A method for treating a neoplastic lesion or surrounding tissue which comprises:
introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement consisting essentially of a physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass, including at least one cytotoxic drug or proliferation inhibitor uniformly dispersed in said composition;
whereby said .Iadd.. .. .drug.!..!..Iaddend. .Badd.cytotoxic drug or proliferation inhibitor .Baddend..Iadd.is slowly released into the .Iadd.. .. .immediate environment.!..!..Iaddend. .Badd.neoplastic lesion or surrounding tissue .Baddend..Iadd.avoiding significant levels of .Iaddend..Iadd.. .. .the drug.!..!..Iaddend. .Badd.said cytotoxic drug or proliferation inhibitor .Baddend..Iadd.at sites distant from the site of
introduction. .Iaddend..Iadd.16. A method for treating a hyperproliferative lesion or surrounding tissue which comprises:
introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement consisting essentially of a physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass, including at least one cytotoxic drug or proliferation inhibitor uniformly dispersed in said composition;
whereby said .Iaddend..Iadd.. .. .drug.!..!..Iaddend. .Badd.cytotoxic drug or proliferation inhibitor .Baddend..Iadd.is slowly released into the .Iadd.. .. .immediate environment.!..!..Iaddend. .Badd.hyperproliferative lesion or surrounding tissue .Baddend..Iadd.avoiding significant levels of .Iaddend..Iadd.. .. .the drug.!..!..Iaddend. .Badd.said cytotoxic drug or proliferation inhibitor .Baddend..Iadd.at sites distant from the site of introduction. .Iaddend.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/574,498 USRE35748E (en) | 1984-05-29 | 1995-12-19 | Treatments employing drug containing matrices for introduction into cellular lesion areas |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61500884A | 1984-05-29 | 1984-05-29 | |
US06/736,496 US4619913A (en) | 1984-05-29 | 1985-05-21 | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
US07/255,863 USRE33375E (en) | 1984-05-29 | 1988-10-11 | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
US08/574,498 USRE35748E (en) | 1984-05-29 | 1995-12-19 | Treatments employing drug containing matrices for introduction into cellular lesion areas |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US61500884A Continuation-In-Part | 1984-05-29 | 1984-05-29 | |
US06/736,496 Reissue US4619913A (en) | 1984-05-29 | 1985-05-21 | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE35748E true USRE35748E (en) | 1998-03-17 |
Family
ID=27400909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/574,498 Expired - Lifetime USRE35748E (en) | 1984-05-29 | 1995-12-19 | Treatments employing drug containing matrices for introduction into cellular lesion areas |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE35748E (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020028243A1 (en) * | 1998-09-25 | 2002-03-07 | Masters David B. | Protein matrix materials, devices and methods of making and using thereof |
US6361551B1 (en) | 1998-12-11 | 2002-03-26 | C. R. Bard, Inc. | Collagen hemostatic fibers |
US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
US6589998B1 (en) | 1999-06-11 | 2003-07-08 | Cytyc Health Corporation | Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue |
WO2003094846A2 (en) | 2002-05-08 | 2003-11-20 | Terman David S | Intrathecal and intratumoral superantigens to treat malignant disease |
US20050147690A1 (en) * | 1998-09-25 | 2005-07-07 | Masters David B. | Biocompatible protein particles, particle devices and methods thereof |
US20050196440A1 (en) * | 2003-12-08 | 2005-09-08 | Masters David B. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US20060073207A1 (en) * | 2003-08-26 | 2006-04-06 | Masters David B | Protein biomaterials and biocoacervates and methods of making and using thereof |
US7119062B1 (en) | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
US20100143487A1 (en) * | 2007-12-26 | 2010-06-10 | Gel-Del Technologies, Inc. | Biocompatible protein-based particles and methods thereof |
US8465537B2 (en) | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
US8623393B2 (en) | 2002-04-29 | 2014-01-07 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
US20150141619A1 (en) * | 2012-11-19 | 2015-05-21 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
US10016534B2 (en) | 2008-11-17 | 2018-07-10 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
US10335433B2 (en) | 2013-04-10 | 2019-07-02 | Mimedx Group, Inc. | NDGA polymers and metal complexes thereof |
US10441664B2 (en) | 2012-11-19 | 2019-10-15 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US10888618B2 (en) * | 2012-09-21 | 2021-01-12 | Intensity Therapeutics, Inc. | Method of treating cancer |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2589210A (en) * | 1945-09-24 | 1952-03-18 | Parke Davis & Co | Therapeutic compositions |
US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
JPS56122317A (en) * | 1980-02-29 | 1981-09-25 | Koken:Kk | Drug transporting material and its preparation |
US4322398A (en) * | 1978-02-20 | 1982-03-30 | Battelle Institut E.V. | Implantable drug depot and process for the production thereof |
US4347234A (en) * | 1978-01-09 | 1982-08-31 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Medicinally useful, shaped mass of collagen resorbable in the body |
US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
US4391797A (en) * | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
EP0083868A1 (en) * | 1982-01-11 | 1983-07-20 | COLLAGEN CORPORATION (a California corporation) | Collagen implant material for augmenting soft tissue |
EP0086627A1 (en) * | 1982-02-12 | 1983-08-24 | Unitika Ltd. | Anti-cancer device |
US4407787A (en) * | 1980-10-03 | 1983-10-04 | Dr. Ruhland Nachf. Gmbh | Collagenous dressing |
-
1995
- 1995-12-19 US US08/574,498 patent/USRE35748E/en not_active Expired - Lifetime
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2589210A (en) * | 1945-09-24 | 1952-03-18 | Parke Davis & Co | Therapeutic compositions |
US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
US4391797A (en) * | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
US4347234A (en) * | 1978-01-09 | 1982-08-31 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Medicinally useful, shaped mass of collagen resorbable in the body |
US4322398A (en) * | 1978-02-20 | 1982-03-30 | Battelle Institut E.V. | Implantable drug depot and process for the production thereof |
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
JPS56122317A (en) * | 1980-02-29 | 1981-09-25 | Koken:Kk | Drug transporting material and its preparation |
US4407787A (en) * | 1980-10-03 | 1983-10-04 | Dr. Ruhland Nachf. Gmbh | Collagenous dressing |
US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
EP0083868A1 (en) * | 1982-01-11 | 1983-07-20 | COLLAGEN CORPORATION (a California corporation) | Collagen implant material for augmenting soft tissue |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
EP0086627A1 (en) * | 1982-02-12 | 1983-08-24 | Unitika Ltd. | Anti-cancer device |
US4536387A (en) * | 1982-02-12 | 1985-08-20 | Unitika Ltd. | Anti-cancer device |
Non-Patent Citations (9)
Title |
---|
Bier et al, Cancer (1979), 44:1194 1200. * |
Bier et al, Cancer (1979), 44:1194-1200. |
Macek et al, Abstracts of Immunology, 4109, p. 1053 (1977). * |
Maugh, Science (1981), 212:1128 1129. * |
Maugh, Science (1981), 212:1128-1129. |
McLaughlin et al, Cancer Research (1978), 38:1311 1316. * |
McLaughlin et al, Cancer Research (1978), 38:1311-1316. |
Miyata et al, Cancer Research (1983), 43:4670 4675. * |
Miyata et al, Cancer Research (1983), 43:4670-4675. |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020028243A1 (en) * | 1998-09-25 | 2002-03-07 | Masters David B. | Protein matrix materials, devices and methods of making and using thereof |
US20050147690A1 (en) * | 1998-09-25 | 2005-07-07 | Masters David B. | Biocompatible protein particles, particle devices and methods thereof |
US8871267B2 (en) | 1998-09-25 | 2014-10-28 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6361551B1 (en) | 1998-12-11 | 2002-03-26 | C. R. Bard, Inc. | Collagen hemostatic fibers |
US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
US6589998B1 (en) | 1999-06-11 | 2003-07-08 | Cytyc Health Corporation | Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue |
US20040013639A1 (en) * | 1999-06-11 | 2004-01-22 | Cytyc Health Corporation | Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue |
US7119062B1 (en) | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
US8623393B2 (en) | 2002-04-29 | 2014-01-07 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
WO2003094846A2 (en) | 2002-05-08 | 2003-11-20 | Terman David S | Intrathecal and intratumoral superantigens to treat malignant disease |
US8465537B2 (en) | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
US8153591B2 (en) | 2003-08-26 | 2012-04-10 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
US20060073207A1 (en) * | 2003-08-26 | 2006-04-06 | Masters David B | Protein biomaterials and biocoacervates and methods of making and using thereof |
US9107937B2 (en) | 2003-08-26 | 2015-08-18 | Gel-Del Technologies, Inc. | Wound treatments with crosslinked protein amorphous biomaterials |
US9999705B2 (en) | 2003-08-26 | 2018-06-19 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
US8529939B2 (en) | 2003-12-08 | 2013-09-10 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US20050196440A1 (en) * | 2003-12-08 | 2005-09-08 | Masters David B. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US20100143487A1 (en) * | 2007-12-26 | 2010-06-10 | Gel-Del Technologies, Inc. | Biocompatible protein-based particles and methods thereof |
US11890371B2 (en) | 2007-12-26 | 2024-02-06 | Petvivo Holdings, Inc. | Biocompatible protein-based particles and methods thereof |
US10016534B2 (en) | 2008-11-17 | 2018-07-10 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
US10888618B2 (en) * | 2012-09-21 | 2021-01-12 | Intensity Therapeutics, Inc. | Method of treating cancer |
US10159744B2 (en) * | 2012-11-19 | 2018-12-25 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
US10441664B2 (en) | 2012-11-19 | 2019-10-15 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US20150141619A1 (en) * | 2012-11-19 | 2015-05-21 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
US10335433B2 (en) | 2013-04-10 | 2019-07-02 | Mimedx Group, Inc. | NDGA polymers and metal complexes thereof |
US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE33375E (en) | Treatments employing drug-containing matrices for introduction into cellular lesion areas | |
USRE35748E (en) | Treatments employing drug containing matrices for introduction into cellular lesion areas | |
US4978332A (en) | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas | |
US5597578A (en) | TGF-β protein compositions for inhibition of cell proliferation | |
US4832686A (en) | Method for administering interleukin-2 | |
US20240139096A1 (en) | Radiation sensitizer of anti-cancer chemotherapy sensitizer | |
JPS6226218A (en) | Remedy for cancerous tumor netastasis | |
US5679638A (en) | Method for treating a tumor with a chemotherapeutic agent | |
KR20010108229A (en) | Use of lipoic acid combination with ascorbic acid in the treatment of cancer | |
EP0138216A2 (en) | Sustained-release IFN preparation for parenteral administration | |
EP0140255B1 (en) | Sustained-release injections | |
JPH0390025A (en) | Antitumor agent | |
EP0825848B1 (en) | Translucent collagen formulations | |
EP0328389B1 (en) | Compostions for treating intracranial tumors | |
US7608612B2 (en) | Radiosensitizer formulations and methods for use | |
US5776898A (en) | Method for treating a tumor with a chemotherapeutic agent | |
Saba et al. | Circulating immunoreactive and bioassayable opsonic plasma fibronectin during experimental tumour growth | |
US20080038376A1 (en) | Anti-cancer composition and method for using the same | |
WO2003041645A2 (en) | Method of vaccinating a human patient to prevent metastatic tumors | |
Teicher et al. | Effect of pH, oxygenation, and temperature on the cytotoxicity and radiosensitization by etanidazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: BIOMEDICINES, INC., CALIFORNIA Free format text: ASSIGNMENT & SCHEDULE 1 PATENTS;ASSIGNOR:MATRIX PHARMACEUTICAL, INC.;REEL/FRAME:013879/0267 Effective date: 20021107 |